- Home
- GT vs GLPG Comparison
GT vs GLPG Comparison
Compare GT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GT
- GLPG
- Stock Information
- Founded
- GT 1898
- GLPG 1999
- Country
- GT United States
- GLPG Belgium
- Employees
- GT N/A
- GLPG N/A
- Industry
- GT Automotive Aftermarket
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- GT Consumer Discretionary
- GLPG Health Care
- Exchange
- GT Nasdaq
- GLPG Nasdaq
- Market Cap
- GT 2.0B
- GLPG 2.1B
- IPO Year
- GT N/A
- GLPG 2005
- Fundamental
- Price
- GT $7.58
- GLPG $31.38
- Analyst Decision
- GT Buy
- GLPG Hold
- Analyst Count
- GT 4
- GLPG 4
- Target Price
- GT $11.38
- GLPG $31.33
- AVG Volume (30 Days)
- GT 9.3M
- GLPG 220.1K
- Earning Date
- GT 11-03-2025
- GLPG 11-05-2025
- Dividend Yield
- GT N/A
- GLPG N/A
- EPS Growth
- GT N/A
- GLPG N/A
- EPS
- GT N/A
- GLPG N/A
- Revenue
- GT $18,310,000,000.00
- GLPG $336,643,201.00
- Revenue This Year
- GT N/A
- GLPG $1.77
- Revenue Next Year
- GT $0.63
- GLPG $0.44
- P/E Ratio
- GT N/A
- GLPG N/A
- Revenue Growth
- GT N/A
- GLPG 10.31
- 52 Week Low
- GT $6.51
- GLPG $22.36
- 52 Week High
- GT $12.03
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- GT 54.55
- GLPG 45.19
- Support Level
- GT $6.76
- GLPG $29.81
- Resistance Level
- GT $8.16
- GLPG $31.85
- Average True Range (ATR)
- GT 0.27
- GLPG 0.88
- MACD
- GT 0.13
- GLPG -0.09
- Stochastic Oscillator
- GT 58.21
- GLPG 44.66
About GT The Goodyear Tire & Rubber Company
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.